261 related articles for article (PubMed ID: 27964820)
1. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
Mirzaei R; Sarkar S; Yong VW
Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
[TBL] [Abstract][Full Text] [Related]
2. The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Luksik AS; Maxwell R; Garzon-Muvdi T; Lim M
Neurotherapeutics; 2017 Oct; 14(4):1049-1065. PubMed ID: 28258545
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.
Kouidhi S; Ben Ayed F; Benammar Elgaaied A
Front Immunol; 2018; 9():353. PubMed ID: 29527212
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for the treatment of glioblastoma.
Thomas AA; Ernstoff MS; Fadul CE
Cancer J; 2012; 18(1):59-68. PubMed ID: 22290259
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Kean LS; Turka LA; Blazar BR
Immunol Rev; 2017 Mar; 276(1):192-212. PubMed ID: 28258702
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Improving responses to immunotherapy in glioblastoma multiforme.
McArdle SEB; Nagarajan D; Barish ME
Front Immunol; 2024; 15():1407930. PubMed ID: 38715607
[No Abstract] [Full Text] [Related]
8. Glioblastoma-activated pericytes support tumor growth via immunosuppression.
Sena IFG; Paiva AE; Prazeres PHDM; Azevedo PO; Lousado L; Bhutia SK; Salmina AB; Mintz A; Birbrair A
Cancer Med; 2018 Apr; 7(4):1232-1239. PubMed ID: 29479841
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of Eph receptors in glioblastoma.
Ferluga S; Tomé CM; Herpai DM; D'Agostino R; Debinski W
Oncotarget; 2016 Sep; 7(37):59860-59876. PubMed ID: 27494882
[TBL] [Abstract][Full Text] [Related]
10. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies.
Jansen JA; Omuro A; Lucca LE
Curr Opin Neurol; 2021 Dec; 34(6):827-833. PubMed ID: 34569985
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies.
Afshari AR; Sanati M; Ahmadi SS; Kesharwani P; Sahebkar A
Cancer Lett; 2024 Jul; 593():216955. PubMed ID: 38750720
[TBL] [Abstract][Full Text] [Related]
12. Introduction to checkpoint inhibitors and cancer immunotherapy.
Sharpe AH
Immunol Rev; 2017 Mar; 276(1):5-8. PubMed ID: 28258698
[No Abstract] [Full Text] [Related]
13. Overview of current immunotherapeutic strategies for glioma.
Calinescu AA; Kamran N; Baker G; Mineharu Y; Lowenstein PR; Castro MG
Immunotherapy; 2015; 7(10):1073-104. PubMed ID: 26598957
[TBL] [Abstract][Full Text] [Related]
14. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
Mock A; Zschäbitz S; Kirsten R; Scheffler M; Wolf B; Herold-Mende C; Kramer R; Busch E; Jenzer M; Jäger D; Grüllich C
Cancer Immunol Immunother; 2019 Dec; 68(12):2005-2014. PubMed ID: 31701161
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in CNS cancers: the role of immune cell trafficking.
Ratnam NM; Gilbert MR; Giles AJ
Neuro Oncol; 2019 Jan; 21(1):37-46. PubMed ID: 29771386
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity and individualized treatment of microenvironment in glioblastoma (Review).
Kang W; Mo Z; Li W; Ma H; Zhang Q
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37888767
[TBL] [Abstract][Full Text] [Related]
17. IFN-λ cancer immunotherapy: new kid on the block.
Lasfar A; Gogas H; Zloza A; Kaufman HL; Kirkwood JM
Immunotherapy; 2016 Jul; 8(8):877-88. PubMed ID: 27381684
[TBL] [Abstract][Full Text] [Related]
18. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
Singh K; Batich KA; Wen PY; Tan AC; Bagley SJ; Lim M; Platten M; Colman H; Ashley DM; Chang SM; Rahman R; Galanis E; Mansouri A; Puduvalli VK; Reardon DA; Sahebjam S; Sampson JH; Simes J; Berry DA; Zadeh G; Cloughesy TF; Mehta MP; Piantadosi S; Weller M; Heimberger AB; Khasraw M
Clin Cancer Res; 2022 Feb; 28(4):585-593. PubMed ID: 34561270
[TBL] [Abstract][Full Text] [Related]
19. Understanding innate immune response in glioblastoma in search of a way forward.
Pant A; Lim M
Neuro Oncol; 2020 Apr; 22(4):444-445. PubMed ID: 32090256
[No Abstract] [Full Text] [Related]
20. The network of immunosuppressive pathways in glioblastoma.
Mangani D; Weller M; Roth P
Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
